Inertia Based Microfluidic Capture and Characterisation of Circulating Tumour Cells for the Diagnosis of Lung Cancer

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2017 Feb 3

PMID 28149842

Citations 13

Authors

Dimple Y Chudasama

Daria V Freydina

Maxim B Freidin

Maria Leung

Angeles Montero Fernandez

Alexandra Rice

Andrew G Nicholson

Emmanouil Karteris

Vladimir Anikin

Eric Lim

Affiliations

Soon will be listed here.

Abstract

Background: Routine clinical application of circulating tumour cells (CTCs) for blood based diagnostics is yet to be established. Despite growing evidence of their clinical utility for diagnosis, prognosis and treatment monitoring, the efficacy of a robust platform and universally accepted diagnostic criteria remain uncertain. We evaluate the diagnostic performance of a microfluidic CTC isolation platform using cytomorphologic criteria in patients undergoing lung cancer surgery.

Methods: Blood was processed from 51 patients undergoing surgery for known or suspected lung cancer using the ClearBridge ClearCell FX system (ClearBridge Biomedics, Singapore). Captured cells were stained on slides with haematoxylin and eosin (H&E) and independently assessed by two pathologist teams. Diagnostic performance was evaluated against the pathologists reported diagnosis of cancer from surgically obtained specimens.

Results: Cancer was diagnosed in 43.1% and 54.9% of all cases. In early stage primary lung cancer, between the two reporting teams, a positive diagnosis of CTCs was made for 50% and 66.7% of patients. The agreement between the reporting teams was 80.4%, corresponding to a kappa-statistic of 0.61±0.11 (P<0.001), indicating substantial agreement. Sensitivity levels for the two teams were calculated as 59% (95% CI, 41-76%) and 41% (95% CI, 24-59%), with a specificity of 53% for both.

Conclusions: The performance of the tested microfluidic antibody independent device to capture CTCs using standard cytomorphological criteria provides the potential of a diagnostic blood test for lung cancer.

Citing Articles

Assessment of Different Circulating Tumor Cell Platforms for Uveal Melanoma: Potential Impact for Future Routine Clinical Practice.

Martel A, Mograbi B, Romeo B, Gastaud L, Lalvee S, Zahaf K Int J Mol Sci. 2023; 24(13).

PMID: 37446253 PMC: 10342234. DOI: 10.3390/ijms241311075.

Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer.

Acheampong E, Abed A, Morici M, Spencer I, Beasley A, Bowyer S Transl Lung Cancer Res. 2022; 11(3):440-451.

PMID: 35399573 PMC: 8988079. DOI: 10.21037/tlcr-21-819.

Simultaneous detection of protein expression of multiple tumor markers of circulating tumor cells and heteroploid of chromosome 8 in primary lung cancer.

Yao H, Wang Z, Yang J, Xu X, Song Y Ann Transl Med. 2022; 9(24):1772.

PMID: 35071466 PMC: 8756229. DOI: 10.21037/atm-21-6346.

Inertial Microfluidics Enabling Clinical Research.

Kalyan S, Torabi C, Khoo H, Sung H, Choi S, Wang W Micromachines (Basel). 2021; 12(3).

PMID: 33802356 PMC: 7999476. DOI: 10.3390/mi12030257.

The Diagnostic and Prognostic Value of a Liquid Biopsy for Esophageal Cancer: A Systematic Review and Meta-Analysis.

Matsushita D, Arigami T, Okubo K, Sasaki K, Noda M, Kita Y Cancers (Basel). 2020; 12(10).

PMID: 33096708 PMC: 7589026. DOI: 10.3390/cancers12103070.

References

Krebs M, Hou J, Sloane R, Lancashire L, Priest L, Nonaka D . Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol. 2011; 7(2):306-15. DOI: 10.1097/JTO.0b013e31823c5c16. View

Hou H, Warkiani M, Khoo B, Li Z, Soo R, Tan D . Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep. 2013; 3:1259. PMC: 3569917. DOI: 10.1038/srep01259. View

Sorber L, Zwaenepoel K, Deschoolmeester V, Van Schil P, Van Meerbeeck J, Lardon F . Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Lung Cancer. 2016; 107:100-107. DOI: 10.1016/j.lungcan.2016.04.026. View

Freidin M, Freydina D, Leung M, Fernandez A, Nicholson A, Lim E . Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. Clin Chem. 2015; 61(10):1299-304. DOI: 10.1373/clinchem.2015.242453. View

Carter L, Metcalf R, Blackhall F, Dive C, Krebs M . Biology and clinical relevance of circulating tumour cells. J Thorac Dis. 2012; 4(5):453-5. PMC: 3461082. DOI: 10.3978/j.issn.2072-1439.2012.09.02. View

Zheng D, Ye X, Zhang M, Sun Y, Wang J, Ni J . Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep. 2016; 6:20913. PMC: 4751431. DOI: 10.1038/srep20913. View

Freidin M, Tay A, Freydina D, Chudasama D, Nicholson A, Rice A . An assessment of diagnostic performance of a filter-based antibody-independent peripheral blood circulating tumour cell capture paired with cytomorphologic criteria for the diagnosis of cancer. Lung Cancer. 2014; 85(2):182-5. DOI: 10.1016/j.lungcan.2014.05.017. View

Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F . A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer. 2011; 105(6):847-53. PMC: 3171010. DOI: 10.1038/bjc.2011.294. View

Cho E . Circulating tumor cells as emerging tumor biomarkers in lung cancer. J Thorac Dis. 2012; 4(5):444-5. PMC: 3461062. DOI: 10.3978/j.issn.2072-1439.2012.08.13. View

10.

Chabon J, Simmons A, Lovejoy A, Esfahani M, Newman A, Haringsma H . Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016; 7:11815. PMC: 4906406. DOI: 10.1038/ncomms11815. View

11.

Joosse S, Gorges T, Pantel K . Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2014; 7(1):1-11. PMC: 4309663. DOI: 10.15252/emmm.201303698. View

12.

Hofman V, Ilie M, Long E, Selva E, Bonnetaud C, Molina T . Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method. Int J Cancer. 2010; 129(7):1651-60. DOI: 10.1002/ijc.25819. View

13.

Lim E, Tay A, Von Der Thusen J, Freidin M, Anikin V, Nicholson A . Clinical results of microfluidic antibody-independent peripheral blood circulating tumor cell capture for the diagnosis of lung cancer. J Thorac Cardiovasc Surg. 2013; 147(6):1936-8. DOI: 10.1016/j.jtcvs.2013.09.052. View

14.

Hou J, Krebs M, Ward T, Sloane R, Priest L, Hughes A . Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol. 2011; 178(3):989-96. PMC: 3069884. DOI: 10.1016/j.ajpath.2010.12.003. View

15.

Hofman V, Ilie M, Bonnetaud C, Selva E, Long E, Molina T . Cytopathologic detection of circulating tumor cells using the isolation by size of epithelial tumor cell method: promises and pitfalls. Am J Clin Pathol. 2010; 135(1):146-56. DOI: 10.1309/AJCP9X8OZBEIQVVI. View

16.

Wang S, Thomas A, Lee E, Yang S, Cheng X, Liu Y . Highly efficient and selective isolation of rare tumor cells using a microfluidic chip with wavy-herringbone micro-patterned surfaces. Analyst. 2016; 141(7):2228-37. PMC: 5051543. DOI: 10.1039/c6an00236f. View

17.

Gupta V, Jafferji I, Garza M, Melnikova V, Hasegawa D, Pethig R . ApoStream(™), a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood. Biomicrofluidics. 2013; 6(2):24133. PMC: 3396706. DOI: 10.1063/1.4731647. View

18.

Kurihara T, Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Tsuji S . Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepatobiliary Pancreat Surg. 2008; 15(2):189-95. DOI: 10.1007/s00534-007-1250-5. View

19.

Karhade M, Hall C, Mishra P, Anderson A, Kuerer H, Bedrosian I . Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2014; 147(2):325-33. PMC: 4149877. DOI: 10.1007/s10549-014-3103-7. View

20.

Satelli A, Brownlee Z, Mitra A, Meng Q, Li S . Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response. Clin Chem. 2014; 61(1):259-66. PMC: 4360893. DOI: 10.1373/clinchem.2014.228122. View